LAUSANNE, Switzerland, September 17, 2024–(BUSINESS WIRE)–Neo Medical SA (Neo), a Swiss know-how firm specializing in spine surgical procedure, has introduced the profitable completion of its Sequence B financing spherical, together with the conversion of present shareholder loans. With this financing spherical, Neo has secured a further fairness funding of as much as $68 million (CHF 58 million) to speed up its international development.
Led by Gyrus Capital SA (Gyrus), alongside the participation of present buyers, together with founders Vincent Lefauconnier and Jonas Larsson, this landmark spherical is among the most vital within the spine business within the final decade.
The proceeds will probably be used to extend Neo’s market share in key areas with an instantaneous deal with increasing the US enterprise, deploying new, complementary, and disruptive merchandise, and enhancing the capabilities of its distinctive AI-driven augmented actuality intraoperative knowledge platform, ADVISE™. With ADVISE™, the corporate’s portfolio of superior surgical applied sciences – Neo Common™ – represents a major step ahead for the $7.6 billion international thoracolumbar fusion market.
“Thoracolumbar spine surgical procedure is a big market that has lacked disruptive innovation for many years – the spine sector wants innovation to enhance affected person outcomes and drive optimistic change for all stakeholders,” mentioned Vincent Lefauconnier, Neo Medical’s CEO and Co-Founder. “That is exactly what we have now got down to obtain with Neo Common™ – a platform introducing new technological and structural approaches to create actual worth each inside and out of doors the working theatre. After efficiently coming into key markets, we’re able to scale. This funding will allow us to develop and push the boundaries of what’s doable in spine surgical procedure, bringing our options to extra healthcare suppliers and, most significantly, bettering outcomes for sufferers.”
“Neo Medical’s imaginative and prescient and product platform has already confirmed itself in Europe and is poised to broaden quickly within the US,” mentioned Dr. Robert Watson, Accomplice and Co-Founding father of Gyrus. “The sustainable commercialization of Neo’s built-in portfolio of applied sciences and revolutionary service mannequin strategically positions the corporate to scale and capitalize on evolving market traits, together with inside outpatient facilities. We’re excited to companion with the administration group and assist Neo’s imaginative and prescient in redefining affected person care.”
Since business launch in 2016, Neo’s applied sciences have been used to deal with round 36,000 sufferers, with the corporate making vital progress in each operational and scientific efficiency in comparison with conventional requirements. Research have proven Neo’s merchandise can lower implant failure charges by as much as three-times, an infection threat by half, and time spent in surgical procedure by as much as 29%, lowering the necessity for revisionary surgical procedure by as a lot as 50%.1-3
Mr. Lefauconnier went on to say, “This elevate is the subsequent step in solidifying Neo Common™ as one of many premier options available on the market. Meant to deal with thoracolumbar sufferers in inpatient and outpatient settings, it helps each MIS and open approaches. Launching prolonged capabilities for complicated surgical procedure will quickly optimize our platform protection from ambulatory surgical procedure to ever extra complicated trauma and deformity.”
About Neo Medical
Neo Medical is a Swiss firm combining the newest advances in biomechanics and intraoperative augmented actuality to set new requirements in spine fusion surgical procedure.
Uniquely designed to assist remedy of any operable thoracolumbar situation in a single procedural platform, the corporate’s portfolio seamlessly integrates proprietary power management applied sciences with first-of-its-kind, intraoperative, AI-driven augmented actuality knowledge capabilities to enhance affected person outcomes, scale back environmental impacts, and decrease healthcare-associated prices.
Coupling its applied sciences with a ‘SmartService’ distribution mannequin, Neo Medical’s providers optimize processes out and in of the OR, enhancing operational effectivity at each stage of the perioperative course of, and contributing to a extra sustainable healthcare system.
With a powerful European presence and confirmed management, the Firm is quickly increasing within the U.S. and elsewhere across the globe. Based mostly close to Lausanne, Switzerland, Neo Medical has working subsidiaries within the US, Spain, France, and Germany. Along with the lead investor Gyrus, its shareholding base contains institutional gamers comparable to Swisscom Ventures, Verve Ventures, 4FO, and Credit score Suisse Entrepreneur Capital. To study extra, please go to www.neo-medical.com.
About Gyrus Capital
Gyrus Capital is a European funding agency devoted to transformational investments within the healthcare and sustainability sectors. Based mostly in Geneva, Switzerland, Gyrus invests in companies that handle the structural wants of society and the setting and are positioned for long-term sustainable development. The agency focuses on complicated transactions, significantly company carve-outs within the €50 million to €500 million vary. A famend group of skilled companions and business specialists helps Gyrus’s energetic funding and value-creation strategy, working carefully with entrepreneurs and managers. To study extra, please go to www.gyruscapital.com.
References:
https://neo-medical.com/press-release-references-1d9e0z/
Contacts:
Neo Medical
Max Howells
max.howells@neo-medical.com
Halsin Companions
Mike Sinclair
msinclair@halsin.com
Discussion about this post